Cryoablation for treatment of peripheral lung metastases from colorectal cancer: a bicenter retrospective study.

IF 4.7 2区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Jean Izaaryene, Rémi Grange, Vincent Habouzit, Sylvain Grange, Bastien Orsini, Michael Dassa, Nassima Daidj, Louis Thierry, Marjorie Ferre, Jean Marc Phelip, Bernard Lelong, Cécile De Chaisemartin, Emmanuel Mitry, Gilles Piana
{"title":"Cryoablation for treatment of peripheral lung metastases from colorectal cancer: a bicenter retrospective study.","authors":"Jean Izaaryene, Rémi Grange, Vincent Habouzit, Sylvain Grange, Bastien Orsini, Michael Dassa, Nassima Daidj, Louis Thierry, Marjorie Ferre, Jean Marc Phelip, Bernard Lelong, Cécile De Chaisemartin, Emmanuel Mitry, Gilles Piana","doi":"10.1007/s00330-024-11153-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the oncological efficacy and complications of cryoablation (CA) in treating lung metastases from colorectal cancer (CRC) at the lung periphery.</p><p><strong>Materials and methods: </strong>The inclusion criteria for this bicenter retrospective study included patients with histologically confirmed CRC, with radiologically confirmed lung metastases at the periphery of the lung (distance of less than or equal to 2 cm from the costal, diaphragmatic, or cervical pleura) treated with CA between January 2017 and June 2022. Patients with intra-parenchymal metastases or metastases close to the mediastinal pleura and patients without follow-up were excluded.</p><p><strong>Results: </strong>Seventy-three patients were included (median age: 69 years, range 47.0-83.0; 38 males, 52.0%) with 113 metastases and 89 procedures. Technical success was achieved in all procedures. During follow-up (median 22 months), on a per metastasis basis, local recurrence occurred for 8/113 (7%) of the metastases in 7 patients at a median time of 19 months; 7 had concomitant distant recurrence. Local progression-free survival rates were 95% at 1 year and 89% at 2, 3, and 4 years. Distant progression occurred in 41/73 (56.2%) patients, significantly associated with a history of liver metastasis and synchronous lung metastasis (p < 0.05). The median chemotherapy-free survival was 14 (IQR (5.0-21.5)) months. Complications were predominantly mild or moderate, with a low incidence of severe complications.</p><p><strong>Conclusion: </strong>CA demonstrates high rate of local control and appears well-tolerated in the treatment of peripheral lung metastases from CRC. The procedure offers a viable therapeutic option, allowing patients a significant period without chemotherapy.</p><p><strong>Key points: </strong>Question Despite its advantages over surgery, data on cryoablation of metastases from colorectal cancer at the periphery of the lung are lacking. Findings Cryoablation enabled very good local control, with local progression-free survival rates of 95% at 1 year and 89% at 2, 3, and 4 years. Clinical relevance Cryoablation is an effective treatment for local tumor control of lung metastases from colorectal cancer at the periphery of the lung. The treatment is well tolerated and can provide patients with substantial relief from chemotherapy.</p>","PeriodicalId":12076,"journal":{"name":"European Radiology","volume":" ","pages":""},"PeriodicalIF":4.7000,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Radiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00330-024-11153-0","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: To evaluate the oncological efficacy and complications of cryoablation (CA) in treating lung metastases from colorectal cancer (CRC) at the lung periphery.

Materials and methods: The inclusion criteria for this bicenter retrospective study included patients with histologically confirmed CRC, with radiologically confirmed lung metastases at the periphery of the lung (distance of less than or equal to 2 cm from the costal, diaphragmatic, or cervical pleura) treated with CA between January 2017 and June 2022. Patients with intra-parenchymal metastases or metastases close to the mediastinal pleura and patients without follow-up were excluded.

Results: Seventy-three patients were included (median age: 69 years, range 47.0-83.0; 38 males, 52.0%) with 113 metastases and 89 procedures. Technical success was achieved in all procedures. During follow-up (median 22 months), on a per metastasis basis, local recurrence occurred for 8/113 (7%) of the metastases in 7 patients at a median time of 19 months; 7 had concomitant distant recurrence. Local progression-free survival rates were 95% at 1 year and 89% at 2, 3, and 4 years. Distant progression occurred in 41/73 (56.2%) patients, significantly associated with a history of liver metastasis and synchronous lung metastasis (p < 0.05). The median chemotherapy-free survival was 14 (IQR (5.0-21.5)) months. Complications were predominantly mild or moderate, with a low incidence of severe complications.

Conclusion: CA demonstrates high rate of local control and appears well-tolerated in the treatment of peripheral lung metastases from CRC. The procedure offers a viable therapeutic option, allowing patients a significant period without chemotherapy.

Key points: Question Despite its advantages over surgery, data on cryoablation of metastases from colorectal cancer at the periphery of the lung are lacking. Findings Cryoablation enabled very good local control, with local progression-free survival rates of 95% at 1 year and 89% at 2, 3, and 4 years. Clinical relevance Cryoablation is an effective treatment for local tumor control of lung metastases from colorectal cancer at the periphery of the lung. The treatment is well tolerated and can provide patients with substantial relief from chemotherapy.

冷冻消融治疗结直肠癌肺外周转移:一项双中心回顾性研究。
目的评估冷冻消融术(CA)治疗结直肠癌(CRC)肺外周转移灶的肿瘤学疗效和并发症:这项双中心回顾性研究的纳入标准包括2017年1月至2022年6月期间接受CA治疗的经组织学确诊的CRC患者,以及经放射学确诊的肺外周肺转移灶(距离肋膜、膈肌或颈胸膜小于或等于2厘米)患者。排除了肺实质内转移或靠近纵隔胸膜转移的患者以及没有随访的患者:共纳入73例患者(中位年龄:69岁,范围47.0-83.0;男性38例,52.0%),转移灶113个,手术89例。所有手术均取得了技术成功。在随访期间(中位数为 22 个月),按转移灶计算,7 名患者的 8/113 个转移灶(7%)出现局部复发,中位时间为 19 个月;7 名患者同时出现远处复发。局部无进展生存率在 1 年时达到 95%,在 2、3 和 4 年时达到 89%。41/73(56.2%)例患者出现远处转移,这与肝转移和同步肺转移病史密切相关(P 结论:CA 的局部控制率较高,但远处转移的发生率较低:CA 在治疗 CRC 周围肺转移方面具有较高的局部控制率和良好的耐受性。该手术提供了一种可行的治疗方案,使患者在相当长的一段时间内无需化疗:问题 尽管冷冻消融术比外科手术更有优势,但目前还缺乏有关结直肠癌肺外周转移灶冷冻消融术的数据。研究结果 低温消融术的局部控制效果非常好,1 年的局部无进展生存率为 95%,2、3 和 4 年的无进展生存率为 89%。临床意义 低温消融术是控制结直肠癌肺外周转移灶局部肿瘤的有效治疗方法。患者对该疗法的耐受性良好,可大大减轻化疗的副作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
European Radiology
European Radiology 医学-核医学
CiteScore
11.60
自引率
8.50%
发文量
874
审稿时长
2-4 weeks
期刊介绍: European Radiology (ER) continuously updates scientific knowledge in radiology by publication of strong original articles and state-of-the-art reviews written by leading radiologists. A well balanced combination of review articles, original papers, short communications from European radiological congresses and information on society matters makes ER an indispensable source for current information in this field. This is the Journal of the European Society of Radiology, and the official journal of a number of societies. From 2004-2008 supplements to European Radiology were published under its companion, European Radiology Supplements, ISSN 1613-3749.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信